You are here

  • Home
  • Archive
  • Volume 9, Issue 8
  • Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers

Article info

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers

Authors

  • Jarushka Naidoo Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USADepartment of Immunology, The Bloomberg–Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, Maryland, USADepartment of Oncology, Beaumont Hospital and RCSI University of Health Sciences, Dublin, Ireland PubMed articlesGoogle scholar articles
  • Karisa C Schreck Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USADepartment of Neurology, John Hopkins Medicine, Johns Hopkins University, Baltimore, Maryland, USADepartment of Neurosurgery, Johns Hopkins University, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Wei Fu Department of Biostatistics, Sidney Kimmel Comprehensive Cancer Center, John Hopkins University, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Chen Hu Department of Biostatistics, Sidney Kimmel Comprehensive Cancer Center, John Hopkins University, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Alexander Carvajal-Gonzalez Department of Neurology, John Hopkins Medicine, Johns Hopkins University, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Roisin M Connolly Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USACancer Research@UCC, College of Medicine and Health, University College Cork, Cork, Ireland PubMed articlesGoogle scholar articles
  • Cesar A Santa-Maria Department of Immunology, The Bloomberg–Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, Maryland, USADepartment of Immunology, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Evan J Lipson Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USADepartment of Immunology, The Bloomberg–Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Matthias Holdhoff Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USADepartment of Neurosurgery, Johns Hopkins University, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Patrick M Forde Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USADepartment of Immunology, The Bloomberg–Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Christopher Douville Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USADepartment of Immunology, The Bloomberg–Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, Maryland, USALudwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University, Baltimore, Maryland, USASol Goldman Pancreatic Cancer Research Center, Johns Hopkins University, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Joanne Riemer Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USADepartment of Immunology, The Bloomberg–Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Amanda Barnes Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USADepartment of Immunology, The Bloomberg–Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Kristin J Redmond Department of Radiation Oncology, Sidney Kimmel Comprehensive Cancer. John Hopkins University, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Lawrence Kleinberg Department of Radiation Oncology, Sidney Kimmel Comprehensive Cancer. John Hopkins University, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Brandi Page Department of Radiation Oncology, Sidney Kimmel Comprehensive Cancer. John Hopkins University, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Nafi Aygun Division of Radiology, Johns Hopkins Hospital, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Kenneth W Kinzler Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USADepartment of Immunology, The Bloomberg–Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, Maryland, USALudwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University, Baltimore, Maryland, USASol Goldman Pancreatic Cancer Research Center, Johns Hopkins University, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Nickolas Papadopoulos Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USADepartment of Immunology, The Bloomberg–Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, Maryland, USALudwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University, Baltimore, Maryland, USASol Goldman Pancreatic Cancer Research Center, Johns Hopkins University, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Chetan Bettegowda Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USADepartment of Immunology, The Bloomberg–Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, Maryland, USADepartment of Neurosurgery, Johns Hopkins University, Baltimore, Maryland, USALudwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University, Baltimore, Maryland, USASol Goldman Pancreatic Cancer Research Center, Johns Hopkins University, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Arun Venkatesan Department of Neurology, John Hopkins Medicine, Johns Hopkins University, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Julie R Brahmer Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USADepartment of Immunology, The Bloomberg–Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Stuart A Grossman Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Jarushka Naidoo; jnaidoo1{at}jhmi.edu
View Full Text

Citation

Naidoo J, Schreck KC, Fu W, et al
Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers
Journal for ImmunoTherapy of Cancer 2021;9:e002473. doi: 10.1136/jitc-2021-002473

Publication history

  • Accepted June 2, 2021
  • First published August 11, 2021.
Online issue publication 
November 02, 2022

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.